Cargando…
The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss...
Autores principales: | Antza, Christina, Nirantharakumar, Krishnarajah, Doundoulakis, Ioannis, Tahrani, Abd A, Toulis, Konstantinos A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709822/ https://www.ncbi.nlm.nih.gov/pubmed/31686781 http://dx.doi.org/10.2147/DDDT.S166765 |
Ejemplares similares
-
The links between sleep duration, obesity and type 2 diabetes mellitus
por: Antza, Christina, et al.
Publicado: (2021) -
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis
por: Kostopoulos, Georgios, et al.
Publicado: (2021) -
Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis
por: Mostafa, Samiul A, et al.
Publicado: (2022) -
The Depiction of Hypertension in Heart Imaging Examinations: An Up-to-Date Review of the Evidence
por: Vasileiadis, Konstantinos, et al.
Publicado: (2023) -
Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database
por: Subramanian, Anuradhaa, et al.
Publicado: (2022)